Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (NCT05132075)
A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.
Who can join: Review the eligibility criteria below.
Location: Valley Medical Center Research — Renton, Washington
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (51 Sites)
Showing the first 25 of 51 sites.
- Valley Medical Center Research — Renton, Washington
- Novartis Investigative Site — CABA, Buenos Aires
- Novartis Investigative Site — Pilar, Buenos Aires
- Novartis Investigative Site — Auchenflower, Queensland
- Novartis Investigative Site — South Brisbane, Queensland
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Sherbrooke, Quebec
- Novartis Investigative Site — Fuzhou, Fujian
- Novartis Investigative Site — Guangzhou, Guangdong
- Novartis Investigative Site — Harbin, Heilongjiang
- Novartis Investigative Site — Changsha, Hunan
- Novartis Investigative Site — Shengyang, Liaoning
- Novartis Investigative Site — Jinan, Shandong
- Novartis Investigative Site — Hangzhou, Zhejiang
- Novartis Investigative Site — Beijing,
- Novartis Investigative Site — Turku,
- Novartis Investigative Site — Athens, GR
- Novartis Investigative Site — Athens,
- Novartis Investigative Site — Heraklion Crete.,
- Novartis Investigative Site — Hong Kong,
- Novartis Investigative Site — Kowloon,
- Novartis Investigative Site — Budapest,
- Novartis Investigative Site — Reykjavik,
- Novartis Investigative Site — Jaipur, Rajasthan
- Novartis Investigative Site — Delhi,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona
Explore by condition: All Non-Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.